American Journal of Cancer Research-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=897913, encodeId=5a3c89e91367, content=这个杂志为啥总是拒了让重投，第一次拒了让加细胞株，第二次又让加WB原始图和标尺重投，大家也是这样吗，这有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af335141421, createdName=haha, createdTime=Mon Nov 09 11:13:38 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799523, encodeId=5343e9952343, content=reviews received是什么状态，我这才审了4天就这个状态，是不是要拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/19/4bf779abd94fdea33ee6fe6f7227bfbd.jpg, createdBy=cf7e87440, createdName=syangl, createdTime=Wed Jun 24 08:40:17 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138813, encodeId=32aa2138813fa, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：有近期投稿的朋友们吗有没有一审修回后杂志要求润色的朋友 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed May 24 14:02:10 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=953146, encodeId=f88f953146ea, content=审稿速度:6.0 经验分享：12-28号投稿，under review 三个月了，还没修回，等的很着急<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a><a href='/topic/show?id=3a3a22925b7' target=_blank style='color:#2F92EE;'>#临床研究#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=527, replyNumber=17, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=22925, encryptionId=3a3a22925b7, topicName=临床研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJTOuGuPUvahz0vz3pNSDZXj4PiciapCMFtm9y8PkmhxXquMNlJjzeH3cppruOfV5HA5cicicTIJwP1Hg/132, createdBy=15015292903, createdName=伟康, createdTime=Thu Apr 01 19:08:03 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953914, encodeId=ebf895391411, content=2019.09.21投稿，9.28rejected因为格式和重复率问题 10.8再次投稿，中间催稿一次，12.4第一次修回，仍是rejected,让加实验修改。 1.22重新投稿，催稿一次，02-25修回以revised 03-13第四次投稿，03.23accepted. 经验:一定要控制重复率，越低越好，我的第一次第二次修回都说了重复率问题。 WB原始图提供带marker的未剪切的原始图，可以参考他们家已发表的文章，别人提供原始图的格式。仔细核对格式要求他们家的实验方法要求写得越细越好，以供其他人能重复出来。这家杂志上了中风险预警杂志，不影响我用来毕业，但如果老师们是评职称评奖啥的需要注意这个情况。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=647d5417917, createdName=ms8000002090283848, createdTime=Mon Apr 05 12:04:49 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913843, encodeId=b78791384336, content=折腾不起！！！2020.9.22投稿，11.4返回让修改后重投，11.15号重投，今天2021.1.5，耗费了近4个月还没有结果……最近又发现这个期刊被警告了……真得是接收了还会担忧，不接收的话真要抑郁一阵了。所以慎投，慎投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75872888334, createdName=冉希, createdTime=Tue Jan 05 10:57:59 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887852, encodeId=06d488e852e5, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志要求细胞实验要做同一组织来源的2株以上细胞实验，而且要有体内实验。不符合这两点要求的话，慎投！<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=641, replyNumber=12, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Thu Sep 24 09:10:52 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809886, encodeId=5521809886fc, content=偏重的研究方向：肿瘤 经验分享：大家好，我投的稿已经Under Review 8 天了没动静，请问你们的稿子多久会据稿或者返回一审意见？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Mon Aug 17 21:12:52 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896865, encodeId=3c00896865a4, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：11.1号投稿 under review 11.4号 review received 11.11号 reject 说是重复高？图片不清楚？还要提供WB原图哦~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b48e9a0952304d79b0ea1ee3838687c6/c82749d52d50482cb8257fa178fa5607.jpg, createdBy=27b62502496, createdName=Seizor, createdTime=Wed Nov 04 14:32:35 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947229, encodeId=b34c94e2290b, content=12月23号投的，现在还是under review，可以发催稿信问问吗？[翻白眼][翻白眼], beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Wed Mar 10 20:42:46 CST 2021, time=2021-03-10, status=1, ipAttribution=)]

2020-11-09 haha

这个杂志为啥总是拒了让重投，第一次拒了让加细胞株，第二次又让加WB原始图和标尺重投，大家也是这样吗，这有希望吗

157 39

展开39条回复

[GetPortalCommentsPageByObjectIdResponse(id=897913, encodeId=5a3c89e91367, content=这个杂志为啥总是拒了让重投，第一次拒了让加细胞株，第二次又让加WB原始图和标尺重投，大家也是这样吗，这有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af335141421, createdName=haha, createdTime=Mon Nov 09 11:13:38 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799523, encodeId=5343e9952343, content=reviews received是什么状态，我这才审了4天就这个状态，是不是要拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/19/4bf779abd94fdea33ee6fe6f7227bfbd.jpg, createdBy=cf7e87440, createdName=syangl, createdTime=Wed Jun 24 08:40:17 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138813, encodeId=32aa2138813fa, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：有近期投稿的朋友们吗有没有一审修回后杂志要求润色的朋友 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed May 24 14:02:10 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=953146, encodeId=f88f953146ea, content=审稿速度:6.0 经验分享：12-28号投稿，under review 三个月了，还没修回，等的很着急<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a><a href='/topic/show?id=3a3a22925b7' target=_blank style='color:#2F92EE;'>#临床研究#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=527, replyNumber=17, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=22925, encryptionId=3a3a22925b7, topicName=临床研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJTOuGuPUvahz0vz3pNSDZXj4PiciapCMFtm9y8PkmhxXquMNlJjzeH3cppruOfV5HA5cicicTIJwP1Hg/132, createdBy=15015292903, createdName=伟康, createdTime=Thu Apr 01 19:08:03 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953914, encodeId=ebf895391411, content=2019.09.21投稿，9.28rejected因为格式和重复率问题 10.8再次投稿，中间催稿一次，12.4第一次修回，仍是rejected,让加实验修改。 1.22重新投稿，催稿一次，02-25修回以revised 03-13第四次投稿，03.23accepted. 经验:一定要控制重复率，越低越好，我的第一次第二次修回都说了重复率问题。 WB原始图提供带marker的未剪切的原始图，可以参考他们家已发表的文章，别人提供原始图的格式。仔细核对格式要求他们家的实验方法要求写得越细越好，以供其他人能重复出来。这家杂志上了中风险预警杂志，不影响我用来毕业，但如果老师们是评职称评奖啥的需要注意这个情况。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=647d5417917, createdName=ms8000002090283848, createdTime=Mon Apr 05 12:04:49 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913843, encodeId=b78791384336, content=折腾不起！！！2020.9.22投稿，11.4返回让修改后重投，11.15号重投，今天2021.1.5，耗费了近4个月还没有结果……最近又发现这个期刊被警告了……真得是接收了还会担忧，不接收的话真要抑郁一阵了。所以慎投，慎投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75872888334, createdName=冉希, createdTime=Tue Jan 05 10:57:59 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887852, encodeId=06d488e852e5, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志要求细胞实验要做同一组织来源的2株以上细胞实验，而且要有体内实验。不符合这两点要求的话，慎投！<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=641, replyNumber=12, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Thu Sep 24 09:10:52 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809886, encodeId=5521809886fc, content=偏重的研究方向：肿瘤 经验分享：大家好，我投的稿已经Under Review 8 天了没动静，请问你们的稿子多久会据稿或者返回一审意见？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Mon Aug 17 21:12:52 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896865, encodeId=3c00896865a4, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：11.1号投稿 under review 11.4号 review received 11.11号 reject 说是重复高？图片不清楚？还要提供WB原图哦~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b48e9a0952304d79b0ea1ee3838687c6/c82749d52d50482cb8257fa178fa5607.jpg, createdBy=27b62502496, createdName=Seizor, createdTime=Wed Nov 04 14:32:35 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947229, encodeId=b34c94e2290b, content=12月23号投的，现在还是under review，可以发催稿信问问吗？[翻白眼][翻白眼], beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Wed Mar 10 20:42:46 CST 2021, time=2021-03-10, status=1, ipAttribution=)]

2020-06-24 syangl

reviews received是什么状态，我这才审了4天就这个状态，是不是要拒了

151 37

展开37条回复

[GetPortalCommentsPageByObjectIdResponse(id=897913, encodeId=5a3c89e91367, content=这个杂志为啥总是拒了让重投，第一次拒了让加细胞株，第二次又让加WB原始图和标尺重投，大家也是这样吗，这有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af335141421, createdName=haha, createdTime=Mon Nov 09 11:13:38 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799523, encodeId=5343e9952343, content=reviews received是什么状态，我这才审了4天就这个状态，是不是要拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/19/4bf779abd94fdea33ee6fe6f7227bfbd.jpg, createdBy=cf7e87440, createdName=syangl, createdTime=Wed Jun 24 08:40:17 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138813, encodeId=32aa2138813fa, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：有近期投稿的朋友们吗有没有一审修回后杂志要求润色的朋友 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed May 24 14:02:10 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=953146, encodeId=f88f953146ea, content=审稿速度:6.0 经验分享：12-28号投稿，under review 三个月了，还没修回，等的很着急<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a><a href='/topic/show?id=3a3a22925b7' target=_blank style='color:#2F92EE;'>#临床研究#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=527, replyNumber=17, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=22925, encryptionId=3a3a22925b7, topicName=临床研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJTOuGuPUvahz0vz3pNSDZXj4PiciapCMFtm9y8PkmhxXquMNlJjzeH3cppruOfV5HA5cicicTIJwP1Hg/132, createdBy=15015292903, createdName=伟康, createdTime=Thu Apr 01 19:08:03 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953914, encodeId=ebf895391411, content=2019.09.21投稿，9.28rejected因为格式和重复率问题 10.8再次投稿，中间催稿一次，12.4第一次修回，仍是rejected,让加实验修改。 1.22重新投稿，催稿一次，02-25修回以revised 03-13第四次投稿，03.23accepted. 经验:一定要控制重复率，越低越好，我的第一次第二次修回都说了重复率问题。 WB原始图提供带marker的未剪切的原始图，可以参考他们家已发表的文章，别人提供原始图的格式。仔细核对格式要求他们家的实验方法要求写得越细越好，以供其他人能重复出来。这家杂志上了中风险预警杂志，不影响我用来毕业，但如果老师们是评职称评奖啥的需要注意这个情况。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=647d5417917, createdName=ms8000002090283848, createdTime=Mon Apr 05 12:04:49 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913843, encodeId=b78791384336, content=折腾不起！！！2020.9.22投稿，11.4返回让修改后重投，11.15号重投，今天2021.1.5，耗费了近4个月还没有结果……最近又发现这个期刊被警告了……真得是接收了还会担忧，不接收的话真要抑郁一阵了。所以慎投，慎投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75872888334, createdName=冉希, createdTime=Tue Jan 05 10:57:59 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887852, encodeId=06d488e852e5, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志要求细胞实验要做同一组织来源的2株以上细胞实验，而且要有体内实验。不符合这两点要求的话，慎投！<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=641, replyNumber=12, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Thu Sep 24 09:10:52 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809886, encodeId=5521809886fc, content=偏重的研究方向：肿瘤 经验分享：大家好，我投的稿已经Under Review 8 天了没动静，请问你们的稿子多久会据稿或者返回一审意见？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Mon Aug 17 21:12:52 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896865, encodeId=3c00896865a4, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：11.1号投稿 under review 11.4号 review received 11.11号 reject 说是重复高？图片不清楚？还要提供WB原图哦~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b48e9a0952304d79b0ea1ee3838687c6/c82749d52d50482cb8257fa178fa5607.jpg, createdBy=27b62502496, createdName=Seizor, createdTime=Wed Nov 04 14:32:35 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947229, encodeId=b34c94e2290b, content=12月23号投的，现在还是under review，可以发催稿信问问吗？[翻白眼][翻白眼], beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Wed Mar 10 20:42:46 CST 2021, time=2021-03-10, status=1, ipAttribution=)]

2023-05-24 gaogao 来自广东省

审稿速度:2.0
偏重的研究方向：肿瘤
经验分享：有近期投稿的朋友们吗有没有一审修回后杂志要求润色的朋友

31 32

展开32条回复

[GetPortalCommentsPageByObjectIdResponse(id=897913, encodeId=5a3c89e91367, content=这个杂志为啥总是拒了让重投，第一次拒了让加细胞株，第二次又让加WB原始图和标尺重投，大家也是这样吗，这有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af335141421, createdName=haha, createdTime=Mon Nov 09 11:13:38 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799523, encodeId=5343e9952343, content=reviews received是什么状态，我这才审了4天就这个状态，是不是要拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/19/4bf779abd94fdea33ee6fe6f7227bfbd.jpg, createdBy=cf7e87440, createdName=syangl, createdTime=Wed Jun 24 08:40:17 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138813, encodeId=32aa2138813fa, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：有近期投稿的朋友们吗有没有一审修回后杂志要求润色的朋友 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed May 24 14:02:10 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=953146, encodeId=f88f953146ea, content=审稿速度:6.0 经验分享：12-28号投稿，under review 三个月了，还没修回，等的很着急<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a><a href='/topic/show?id=3a3a22925b7' target=_blank style='color:#2F92EE;'>#临床研究#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=527, replyNumber=17, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=22925, encryptionId=3a3a22925b7, topicName=临床研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJTOuGuPUvahz0vz3pNSDZXj4PiciapCMFtm9y8PkmhxXquMNlJjzeH3cppruOfV5HA5cicicTIJwP1Hg/132, createdBy=15015292903, createdName=伟康, createdTime=Thu Apr 01 19:08:03 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953914, encodeId=ebf895391411, content=2019.09.21投稿，9.28rejected因为格式和重复率问题 10.8再次投稿，中间催稿一次，12.4第一次修回，仍是rejected,让加实验修改。 1.22重新投稿，催稿一次，02-25修回以revised 03-13第四次投稿，03.23accepted. 经验:一定要控制重复率，越低越好，我的第一次第二次修回都说了重复率问题。 WB原始图提供带marker的未剪切的原始图，可以参考他们家已发表的文章，别人提供原始图的格式。仔细核对格式要求他们家的实验方法要求写得越细越好，以供其他人能重复出来。这家杂志上了中风险预警杂志，不影响我用来毕业，但如果老师们是评职称评奖啥的需要注意这个情况。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=647d5417917, createdName=ms8000002090283848, createdTime=Mon Apr 05 12:04:49 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913843, encodeId=b78791384336, content=折腾不起！！！2020.9.22投稿，11.4返回让修改后重投，11.15号重投，今天2021.1.5，耗费了近4个月还没有结果……最近又发现这个期刊被警告了……真得是接收了还会担忧，不接收的话真要抑郁一阵了。所以慎投，慎投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75872888334, createdName=冉希, createdTime=Tue Jan 05 10:57:59 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887852, encodeId=06d488e852e5, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志要求细胞实验要做同一组织来源的2株以上细胞实验，而且要有体内实验。不符合这两点要求的话，慎投！<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=641, replyNumber=12, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Thu Sep 24 09:10:52 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809886, encodeId=5521809886fc, content=偏重的研究方向：肿瘤 经验分享：大家好，我投的稿已经Under Review 8 天了没动静，请问你们的稿子多久会据稿或者返回一审意见？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Mon Aug 17 21:12:52 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896865, encodeId=3c00896865a4, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：11.1号投稿 under review 11.4号 review received 11.11号 reject 说是重复高？图片不清楚？还要提供WB原图哦~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b48e9a0952304d79b0ea1ee3838687c6/c82749d52d50482cb8257fa178fa5607.jpg, createdBy=27b62502496, createdName=Seizor, createdTime=Wed Nov 04 14:32:35 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947229, encodeId=b34c94e2290b, content=12月23号投的，现在还是under review，可以发催稿信问问吗？[翻白眼][翻白眼], beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Wed Mar 10 20:42:46 CST 2021, time=2021-03-10, status=1, ipAttribution=)]

2021-04-01 伟康

审稿速度:6.0
经验分享：12-28号投稿，under review 三个月了，还没修回，等的很着急#肿瘤##临床研究#

527 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=897913, encodeId=5a3c89e91367, content=这个杂志为啥总是拒了让重投，第一次拒了让加细胞株，第二次又让加WB原始图和标尺重投，大家也是这样吗，这有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af335141421, createdName=haha, createdTime=Mon Nov 09 11:13:38 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799523, encodeId=5343e9952343, content=reviews received是什么状态，我这才审了4天就这个状态，是不是要拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/19/4bf779abd94fdea33ee6fe6f7227bfbd.jpg, createdBy=cf7e87440, createdName=syangl, createdTime=Wed Jun 24 08:40:17 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138813, encodeId=32aa2138813fa, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：有近期投稿的朋友们吗有没有一审修回后杂志要求润色的朋友 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed May 24 14:02:10 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=953146, encodeId=f88f953146ea, content=审稿速度:6.0 经验分享：12-28号投稿，under review 三个月了，还没修回，等的很着急<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a><a href='/topic/show?id=3a3a22925b7' target=_blank style='color:#2F92EE;'>#临床研究#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=527, replyNumber=17, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=22925, encryptionId=3a3a22925b7, topicName=临床研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJTOuGuPUvahz0vz3pNSDZXj4PiciapCMFtm9y8PkmhxXquMNlJjzeH3cppruOfV5HA5cicicTIJwP1Hg/132, createdBy=15015292903, createdName=伟康, createdTime=Thu Apr 01 19:08:03 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953914, encodeId=ebf895391411, content=2019.09.21投稿，9.28rejected因为格式和重复率问题 10.8再次投稿，中间催稿一次，12.4第一次修回，仍是rejected,让加实验修改。 1.22重新投稿，催稿一次，02-25修回以revised 03-13第四次投稿，03.23accepted. 经验:一定要控制重复率，越低越好，我的第一次第二次修回都说了重复率问题。 WB原始图提供带marker的未剪切的原始图，可以参考他们家已发表的文章，别人提供原始图的格式。仔细核对格式要求他们家的实验方法要求写得越细越好，以供其他人能重复出来。这家杂志上了中风险预警杂志，不影响我用来毕业，但如果老师们是评职称评奖啥的需要注意这个情况。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=647d5417917, createdName=ms8000002090283848, createdTime=Mon Apr 05 12:04:49 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913843, encodeId=b78791384336, content=折腾不起！！！2020.9.22投稿，11.4返回让修改后重投，11.15号重投，今天2021.1.5，耗费了近4个月还没有结果……最近又发现这个期刊被警告了……真得是接收了还会担忧，不接收的话真要抑郁一阵了。所以慎投，慎投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75872888334, createdName=冉希, createdTime=Tue Jan 05 10:57:59 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887852, encodeId=06d488e852e5, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志要求细胞实验要做同一组织来源的2株以上细胞实验，而且要有体内实验。不符合这两点要求的话，慎投！<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=641, replyNumber=12, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Thu Sep 24 09:10:52 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809886, encodeId=5521809886fc, content=偏重的研究方向：肿瘤 经验分享：大家好，我投的稿已经Under Review 8 天了没动静，请问你们的稿子多久会据稿或者返回一审意见？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Mon Aug 17 21:12:52 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896865, encodeId=3c00896865a4, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：11.1号投稿 under review 11.4号 review received 11.11号 reject 说是重复高？图片不清楚？还要提供WB原图哦~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b48e9a0952304d79b0ea1ee3838687c6/c82749d52d50482cb8257fa178fa5607.jpg, createdBy=27b62502496, createdName=Seizor, createdTime=Wed Nov 04 14:32:35 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947229, encodeId=b34c94e2290b, content=12月23号投的，现在还是under review，可以发催稿信问问吗？[翻白眼][翻白眼], beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Wed Mar 10 20:42:46 CST 2021, time=2021-03-10, status=1, ipAttribution=)]

2021-04-05 ms8000002090283848

2019.09.21投稿，9.28rejected因为格式和重复率问题 10.8再次投稿，中间催稿一次，12.4第一次修回，仍是rejected,让加实验修改。 1.22重新投稿，催稿一次，02-25修回以revised 03-13第四次投稿，03.23accepted. 经验:一定要控制重复率，越低越好，我的第一次第二次修回都说了重复率问题。 WB原始图提供带marker的未剪切的原始图，可以参考他们家已发表的文章，别人提供原始图的格式。仔细核对格式要求他们家的实验方法要求写得越细越好，以供其他人能重复出来。这家杂志上了中风险预警杂志，不影响我用来毕业，但如果老师们是评职称评奖啥的需要注意这个情况。

124 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=897913, encodeId=5a3c89e91367, content=这个杂志为啥总是拒了让重投，第一次拒了让加细胞株，第二次又让加WB原始图和标尺重投，大家也是这样吗，这有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af335141421, createdName=haha, createdTime=Mon Nov 09 11:13:38 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799523, encodeId=5343e9952343, content=reviews received是什么状态，我这才审了4天就这个状态，是不是要拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/19/4bf779abd94fdea33ee6fe6f7227bfbd.jpg, createdBy=cf7e87440, createdName=syangl, createdTime=Wed Jun 24 08:40:17 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138813, encodeId=32aa2138813fa, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：有近期投稿的朋友们吗有没有一审修回后杂志要求润色的朋友 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed May 24 14:02:10 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=953146, encodeId=f88f953146ea, content=审稿速度:6.0 经验分享：12-28号投稿，under review 三个月了，还没修回，等的很着急<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a><a href='/topic/show?id=3a3a22925b7' target=_blank style='color:#2F92EE;'>#临床研究#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=527, replyNumber=17, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=22925, encryptionId=3a3a22925b7, topicName=临床研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJTOuGuPUvahz0vz3pNSDZXj4PiciapCMFtm9y8PkmhxXquMNlJjzeH3cppruOfV5HA5cicicTIJwP1Hg/132, createdBy=15015292903, createdName=伟康, createdTime=Thu Apr 01 19:08:03 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953914, encodeId=ebf895391411, content=2019.09.21投稿，9.28rejected因为格式和重复率问题 10.8再次投稿，中间催稿一次，12.4第一次修回，仍是rejected,让加实验修改。 1.22重新投稿，催稿一次，02-25修回以revised 03-13第四次投稿，03.23accepted. 经验:一定要控制重复率，越低越好，我的第一次第二次修回都说了重复率问题。 WB原始图提供带marker的未剪切的原始图，可以参考他们家已发表的文章，别人提供原始图的格式。仔细核对格式要求他们家的实验方法要求写得越细越好，以供其他人能重复出来。这家杂志上了中风险预警杂志，不影响我用来毕业，但如果老师们是评职称评奖啥的需要注意这个情况。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=647d5417917, createdName=ms8000002090283848, createdTime=Mon Apr 05 12:04:49 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913843, encodeId=b78791384336, content=折腾不起！！！2020.9.22投稿，11.4返回让修改后重投，11.15号重投，今天2021.1.5，耗费了近4个月还没有结果……最近又发现这个期刊被警告了……真得是接收了还会担忧，不接收的话真要抑郁一阵了。所以慎投，慎投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75872888334, createdName=冉希, createdTime=Tue Jan 05 10:57:59 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887852, encodeId=06d488e852e5, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志要求细胞实验要做同一组织来源的2株以上细胞实验，而且要有体内实验。不符合这两点要求的话，慎投！<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=641, replyNumber=12, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Thu Sep 24 09:10:52 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809886, encodeId=5521809886fc, content=偏重的研究方向：肿瘤 经验分享：大家好，我投的稿已经Under Review 8 天了没动静，请问你们的稿子多久会据稿或者返回一审意见？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Mon Aug 17 21:12:52 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896865, encodeId=3c00896865a4, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：11.1号投稿 under review 11.4号 review received 11.11号 reject 说是重复高？图片不清楚？还要提供WB原图哦~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b48e9a0952304d79b0ea1ee3838687c6/c82749d52d50482cb8257fa178fa5607.jpg, createdBy=27b62502496, createdName=Seizor, createdTime=Wed Nov 04 14:32:35 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947229, encodeId=b34c94e2290b, content=12月23号投的，现在还是under review，可以发催稿信问问吗？[翻白眼][翻白眼], beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Wed Mar 10 20:42:46 CST 2021, time=2021-03-10, status=1, ipAttribution=)]

2021-01-05 冉希

折腾不起！！！2020.9.22投稿，11.4返回让修改后重投，11.15号重投，今天2021.1.5，耗费了近4个月还没有结果……最近又发现这个期刊被警告了……真得是接收了还会担忧，不接收的话真要抑郁一阵了。所以慎投，慎投！

94 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=897913, encodeId=5a3c89e91367, content=这个杂志为啥总是拒了让重投，第一次拒了让加细胞株，第二次又让加WB原始图和标尺重投，大家也是这样吗，这有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af335141421, createdName=haha, createdTime=Mon Nov 09 11:13:38 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799523, encodeId=5343e9952343, content=reviews received是什么状态，我这才审了4天就这个状态，是不是要拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/19/4bf779abd94fdea33ee6fe6f7227bfbd.jpg, createdBy=cf7e87440, createdName=syangl, createdTime=Wed Jun 24 08:40:17 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138813, encodeId=32aa2138813fa, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：有近期投稿的朋友们吗有没有一审修回后杂志要求润色的朋友 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed May 24 14:02:10 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=953146, encodeId=f88f953146ea, content=审稿速度:6.0 经验分享：12-28号投稿，under review 三个月了，还没修回，等的很着急<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a><a href='/topic/show?id=3a3a22925b7' target=_blank style='color:#2F92EE;'>#临床研究#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=527, replyNumber=17, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=22925, encryptionId=3a3a22925b7, topicName=临床研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJTOuGuPUvahz0vz3pNSDZXj4PiciapCMFtm9y8PkmhxXquMNlJjzeH3cppruOfV5HA5cicicTIJwP1Hg/132, createdBy=15015292903, createdName=伟康, createdTime=Thu Apr 01 19:08:03 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953914, encodeId=ebf895391411, content=2019.09.21投稿，9.28rejected因为格式和重复率问题 10.8再次投稿，中间催稿一次，12.4第一次修回，仍是rejected,让加实验修改。 1.22重新投稿，催稿一次，02-25修回以revised 03-13第四次投稿，03.23accepted. 经验:一定要控制重复率，越低越好，我的第一次第二次修回都说了重复率问题。 WB原始图提供带marker的未剪切的原始图，可以参考他们家已发表的文章，别人提供原始图的格式。仔细核对格式要求他们家的实验方法要求写得越细越好，以供其他人能重复出来。这家杂志上了中风险预警杂志，不影响我用来毕业，但如果老师们是评职称评奖啥的需要注意这个情况。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=647d5417917, createdName=ms8000002090283848, createdTime=Mon Apr 05 12:04:49 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913843, encodeId=b78791384336, content=折腾不起！！！2020.9.22投稿，11.4返回让修改后重投，11.15号重投，今天2021.1.5，耗费了近4个月还没有结果……最近又发现这个期刊被警告了……真得是接收了还会担忧，不接收的话真要抑郁一阵了。所以慎投，慎投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75872888334, createdName=冉希, createdTime=Tue Jan 05 10:57:59 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887852, encodeId=06d488e852e5, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志要求细胞实验要做同一组织来源的2株以上细胞实验，而且要有体内实验。不符合这两点要求的话，慎投！<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=641, replyNumber=12, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Thu Sep 24 09:10:52 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809886, encodeId=5521809886fc, content=偏重的研究方向：肿瘤 经验分享：大家好，我投的稿已经Under Review 8 天了没动静，请问你们的稿子多久会据稿或者返回一审意见？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Mon Aug 17 21:12:52 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896865, encodeId=3c00896865a4, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：11.1号投稿 under review 11.4号 review received 11.11号 reject 说是重复高？图片不清楚？还要提供WB原图哦~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b48e9a0952304d79b0ea1ee3838687c6/c82749d52d50482cb8257fa178fa5607.jpg, createdBy=27b62502496, createdName=Seizor, createdTime=Wed Nov 04 14:32:35 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947229, encodeId=b34c94e2290b, content=12月23号投的，现在还是under review，可以发催稿信问问吗？[翻白眼][翻白眼], beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Wed Mar 10 20:42:46 CST 2021, time=2021-03-10, status=1, ipAttribution=)]

2020-09-24 xyls666

审稿速度:1.0 | 投稿命中率:50.0
经验分享：这杂志要求细胞实验要做同一组织来源的2株以上细胞实验，而且要有体内实验。不符合这两点要求的话，慎投！#肿瘤#

641 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=897913, encodeId=5a3c89e91367, content=这个杂志为啥总是拒了让重投，第一次拒了让加细胞株，第二次又让加WB原始图和标尺重投，大家也是这样吗，这有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af335141421, createdName=haha, createdTime=Mon Nov 09 11:13:38 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799523, encodeId=5343e9952343, content=reviews received是什么状态，我这才审了4天就这个状态，是不是要拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/19/4bf779abd94fdea33ee6fe6f7227bfbd.jpg, createdBy=cf7e87440, createdName=syangl, createdTime=Wed Jun 24 08:40:17 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138813, encodeId=32aa2138813fa, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：有近期投稿的朋友们吗有没有一审修回后杂志要求润色的朋友 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed May 24 14:02:10 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=953146, encodeId=f88f953146ea, content=审稿速度:6.0 经验分享：12-28号投稿，under review 三个月了，还没修回，等的很着急<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a><a href='/topic/show?id=3a3a22925b7' target=_blank style='color:#2F92EE;'>#临床研究#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=527, replyNumber=17, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=22925, encryptionId=3a3a22925b7, topicName=临床研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJTOuGuPUvahz0vz3pNSDZXj4PiciapCMFtm9y8PkmhxXquMNlJjzeH3cppruOfV5HA5cicicTIJwP1Hg/132, createdBy=15015292903, createdName=伟康, createdTime=Thu Apr 01 19:08:03 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953914, encodeId=ebf895391411, content=2019.09.21投稿，9.28rejected因为格式和重复率问题 10.8再次投稿，中间催稿一次，12.4第一次修回，仍是rejected,让加实验修改。 1.22重新投稿，催稿一次，02-25修回以revised 03-13第四次投稿，03.23accepted. 经验:一定要控制重复率，越低越好，我的第一次第二次修回都说了重复率问题。 WB原始图提供带marker的未剪切的原始图，可以参考他们家已发表的文章，别人提供原始图的格式。仔细核对格式要求他们家的实验方法要求写得越细越好，以供其他人能重复出来。这家杂志上了中风险预警杂志，不影响我用来毕业，但如果老师们是评职称评奖啥的需要注意这个情况。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=647d5417917, createdName=ms8000002090283848, createdTime=Mon Apr 05 12:04:49 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913843, encodeId=b78791384336, content=折腾不起！！！2020.9.22投稿，11.4返回让修改后重投，11.15号重投，今天2021.1.5，耗费了近4个月还没有结果……最近又发现这个期刊被警告了……真得是接收了还会担忧，不接收的话真要抑郁一阵了。所以慎投，慎投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75872888334, createdName=冉希, createdTime=Tue Jan 05 10:57:59 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887852, encodeId=06d488e852e5, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志要求细胞实验要做同一组织来源的2株以上细胞实验，而且要有体内实验。不符合这两点要求的话，慎投！<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=641, replyNumber=12, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Thu Sep 24 09:10:52 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809886, encodeId=5521809886fc, content=偏重的研究方向：肿瘤 经验分享：大家好，我投的稿已经Under Review 8 天了没动静，请问你们的稿子多久会据稿或者返回一审意见？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Mon Aug 17 21:12:52 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896865, encodeId=3c00896865a4, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：11.1号投稿 under review 11.4号 review received 11.11号 reject 说是重复高？图片不清楚？还要提供WB原图哦~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b48e9a0952304d79b0ea1ee3838687c6/c82749d52d50482cb8257fa178fa5607.jpg, createdBy=27b62502496, createdName=Seizor, createdTime=Wed Nov 04 14:32:35 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947229, encodeId=b34c94e2290b, content=12月23号投的，现在还是under review，可以发催稿信问问吗？[翻白眼][翻白眼], beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Wed Mar 10 20:42:46 CST 2021, time=2021-03-10, status=1, ipAttribution=)]

2020-08-17 xyls666

偏重的研究方向：肿瘤
经验分享：大家好，我投的稿已经Under Review 8 天了没动静，请问你们的稿子多久会据稿或者返回一审意见？谢谢

133 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=897913, encodeId=5a3c89e91367, content=这个杂志为啥总是拒了让重投，第一次拒了让加细胞株，第二次又让加WB原始图和标尺重投，大家也是这样吗，这有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af335141421, createdName=haha, createdTime=Mon Nov 09 11:13:38 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799523, encodeId=5343e9952343, content=reviews received是什么状态，我这才审了4天就这个状态，是不是要拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/19/4bf779abd94fdea33ee6fe6f7227bfbd.jpg, createdBy=cf7e87440, createdName=syangl, createdTime=Wed Jun 24 08:40:17 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138813, encodeId=32aa2138813fa, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：有近期投稿的朋友们吗有没有一审修回后杂志要求润色的朋友 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed May 24 14:02:10 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=953146, encodeId=f88f953146ea, content=审稿速度:6.0 经验分享：12-28号投稿，under review 三个月了，还没修回，等的很着急<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a><a href='/topic/show?id=3a3a22925b7' target=_blank style='color:#2F92EE;'>#临床研究#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=527, replyNumber=17, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=22925, encryptionId=3a3a22925b7, topicName=临床研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJTOuGuPUvahz0vz3pNSDZXj4PiciapCMFtm9y8PkmhxXquMNlJjzeH3cppruOfV5HA5cicicTIJwP1Hg/132, createdBy=15015292903, createdName=伟康, createdTime=Thu Apr 01 19:08:03 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953914, encodeId=ebf895391411, content=2019.09.21投稿，9.28rejected因为格式和重复率问题 10.8再次投稿，中间催稿一次，12.4第一次修回，仍是rejected,让加实验修改。 1.22重新投稿，催稿一次，02-25修回以revised 03-13第四次投稿，03.23accepted. 经验:一定要控制重复率，越低越好，我的第一次第二次修回都说了重复率问题。 WB原始图提供带marker的未剪切的原始图，可以参考他们家已发表的文章，别人提供原始图的格式。仔细核对格式要求他们家的实验方法要求写得越细越好，以供其他人能重复出来。这家杂志上了中风险预警杂志，不影响我用来毕业，但如果老师们是评职称评奖啥的需要注意这个情况。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=647d5417917, createdName=ms8000002090283848, createdTime=Mon Apr 05 12:04:49 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913843, encodeId=b78791384336, content=折腾不起！！！2020.9.22投稿，11.4返回让修改后重投，11.15号重投，今天2021.1.5，耗费了近4个月还没有结果……最近又发现这个期刊被警告了……真得是接收了还会担忧，不接收的话真要抑郁一阵了。所以慎投，慎投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75872888334, createdName=冉希, createdTime=Tue Jan 05 10:57:59 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887852, encodeId=06d488e852e5, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志要求细胞实验要做同一组织来源的2株以上细胞实验，而且要有体内实验。不符合这两点要求的话，慎投！<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=641, replyNumber=12, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Thu Sep 24 09:10:52 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809886, encodeId=5521809886fc, content=偏重的研究方向：肿瘤 经验分享：大家好，我投的稿已经Under Review 8 天了没动静，请问你们的稿子多久会据稿或者返回一审意见？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Mon Aug 17 21:12:52 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896865, encodeId=3c00896865a4, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：11.1号投稿 under review 11.4号 review received 11.11号 reject 说是重复高？图片不清楚？还要提供WB原图哦~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b48e9a0952304d79b0ea1ee3838687c6/c82749d52d50482cb8257fa178fa5607.jpg, createdBy=27b62502496, createdName=Seizor, createdTime=Wed Nov 04 14:32:35 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947229, encodeId=b34c94e2290b, content=12月23号投的，现在还是under review，可以发催稿信问问吗？[翻白眼][翻白眼], beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Wed Mar 10 20:42:46 CST 2021, time=2021-03-10, status=1, ipAttribution=)]

2020-11-04 Seizor

审稿速度:1.0 | 投稿命中率:25.0
经验分享：11.1号投稿 under review
11.4号 review received
11.11号 reject
说是重复高？图片不清楚？还要提供WB原图哦~

103 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=897913, encodeId=5a3c89e91367, content=这个杂志为啥总是拒了让重投，第一次拒了让加细胞株，第二次又让加WB原始图和标尺重投，大家也是这样吗，这有希望吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af335141421, createdName=haha, createdTime=Mon Nov 09 11:13:38 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799523, encodeId=5343e9952343, content=reviews received是什么状态，我这才审了4天就这个状态，是不是要拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/19/4bf779abd94fdea33ee6fe6f7227bfbd.jpg, createdBy=cf7e87440, createdName=syangl, createdTime=Wed Jun 24 08:40:17 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138813, encodeId=32aa2138813fa, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：有近期投稿的朋友们吗有没有一审修回后杂志要求润色的朋友 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed May 24 14:02:10 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=953146, encodeId=f88f953146ea, content=审稿速度:6.0 经验分享：12-28号投稿，under review 三个月了，还没修回，等的很着急<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a><a href='/topic/show?id=3a3a22925b7' target=_blank style='color:#2F92EE;'>#临床研究#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=527, replyNumber=17, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=22925, encryptionId=3a3a22925b7, topicName=临床研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJTOuGuPUvahz0vz3pNSDZXj4PiciapCMFtm9y8PkmhxXquMNlJjzeH3cppruOfV5HA5cicicTIJwP1Hg/132, createdBy=15015292903, createdName=伟康, createdTime=Thu Apr 01 19:08:03 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953914, encodeId=ebf895391411, content=2019.09.21投稿，9.28rejected因为格式和重复率问题 10.8再次投稿，中间催稿一次，12.4第一次修回，仍是rejected,让加实验修改。 1.22重新投稿，催稿一次，02-25修回以revised 03-13第四次投稿，03.23accepted. 经验:一定要控制重复率，越低越好，我的第一次第二次修回都说了重复率问题。 WB原始图提供带marker的未剪切的原始图，可以参考他们家已发表的文章，别人提供原始图的格式。仔细核对格式要求他们家的实验方法要求写得越细越好，以供其他人能重复出来。这家杂志上了中风险预警杂志，不影响我用来毕业，但如果老师们是评职称评奖啥的需要注意这个情况。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=647d5417917, createdName=ms8000002090283848, createdTime=Mon Apr 05 12:04:49 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913843, encodeId=b78791384336, content=折腾不起！！！2020.9.22投稿，11.4返回让修改后重投，11.15号重投，今天2021.1.5，耗费了近4个月还没有结果……最近又发现这个期刊被警告了……真得是接收了还会担忧，不接收的话真要抑郁一阵了。所以慎投，慎投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75872888334, createdName=冉希, createdTime=Tue Jan 05 10:57:59 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887852, encodeId=06d488e852e5, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志要求细胞实验要做同一组织来源的2株以上细胞实验，而且要有体内实验。不符合这两点要求的话，慎投！<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=641, replyNumber=12, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Thu Sep 24 09:10:52 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809886, encodeId=5521809886fc, content=偏重的研究方向：肿瘤 经验分享：大家好，我投的稿已经Under Review 8 天了没动静，请问你们的稿子多久会据稿或者返回一审意见？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40b11700460, createdName=xyls666, createdTime=Mon Aug 17 21:12:52 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896865, encodeId=3c00896865a4, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：11.1号投稿 under review 11.4号 review received 11.11号 reject 说是重复高？图片不清楚？还要提供WB原图哦~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201229/b48e9a0952304d79b0ea1ee3838687c6/c82749d52d50482cb8257fa178fa5607.jpg, createdBy=27b62502496, createdName=Seizor, createdTime=Wed Nov 04 14:32:35 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947229, encodeId=b34c94e2290b, content=12月23号投的，现在还是under review，可以发催稿信问问吗？[翻白眼][翻白眼], beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Wed Mar 10 20:42:46 CST 2021, time=2021-03-10, status=1, ipAttribution=)]

2021-03-10 小鹏友

12月23号投的，现在还是under review，可以发催稿信问问吗？[翻白眼][翻白眼]

108 10

展开10条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务